Highly crosslinked and insoluble basic anion exchange resin used as anticholesteremic. It may also may reduce triglyceride levels.
A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
Flammable, amorphous, vegetable products of secretion or disintegration, usually formed in special cavities of plants. They are generally insoluble in water and soluble in alcohol, carbon tetrachloride, ether, or volatile oils. They are fusible and have a conchoidal fracture. They are the oxidation or polymerization products of the terpenes, and are mixtures of aromatic acids and esters. Most are soft and sticky, but harden after exposure to cold. (From Grant & Hackh's Chemical Dictionary, 5th ed & Dorland, 28th ed)
Hydrazines substituted by one or more methyl groups in any position.
A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.
Hydrazines substituted with two methyl groups in any position.
A group of familial disorders characterized by elevated circulating cholesterol contained in either LOW-DENSITY LIPOPROTEINS alone or also in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins).
Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS.
A syndrome characterized by persistent or recurrent fatigue, diffuse musculoskeletal pain, sleep disturbances, and subjective cognitive impairment of 6 months duration or longer. Symptoms are not caused by ongoing exertion; are not relieved by rest; and result in a substantial reduction of previous levels of occupational, educational, social, or personal activities. Minor alterations of immune, neuroendocrine, and autonomic function may be associated with this syndrome. There is also considerable overlap between this condition and FIBROMYALGIA. (From Semin Neurol 1998;18(2):237-42; Ann Intern Med 1994 Dec 15;121(12): 953-9)
An acute, febrile, infectious disease generally occurring in epidemics. It is usually caused by coxsackieviruses B and sometimes by coxsackieviruses A; echoviruses; or other enteroviruses.
A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence.
A behavior disorder originating in childhood in which the essential features are signs of developmentally inappropriate inattention, impulsivity, and hyperactivity. Although most individuals have symptoms of both inattention and hyperactivity-impulsivity, one or the other pattern may be predominant. The disorder is more frequent in males than females. Onset is in childhood. Symptoms often attenuate during late adolescence although a minority experience the full complement of symptoms into mid-adulthood. (From DSM-V)
A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
Retrograde flow of gastric juice (GASTRIC ACID) and/or duodenal contents (BILE ACIDS; PANCREATIC JUICE) into the distal ESOPHAGUS, commonly due to incompetence of the LOWER ESOPHAGEAL SPHINCTER.
A lipid-regulating agent that lowers elevated serum lipids primarily by decreasing serum triglycerides with a variable reduction in total cholesterol.
A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils.
Substances used to lower plasma CHOLESTEROL levels.
Facilities which provide information concerning poisons and treatment of poisoning in emergencies.
A condition or physical state produced by the ingestion, injection, inhalation of or exposure to a deleterious agent.
The fleshy or dry ripened ovary of a plant, enclosing the seed or seeds.
Substances or materials used in the course of housekeeping or personal routine.
Liquids that are suitable for drinking. (From Merriam Webster Collegiate Dictionary, 10th ed)
Coordination of activities and programs among health care institutions within defined geographic areas for the purpose of improving delivery and quality of medical care to the patients. These programs are mandated under U.S. Public Law 89-239.
Possesses an unusual and selective cytotoxicity for VASCULAR SMOOTH MUSCLE cells in dogs and rats. Useful for experiments dealing with arterial injury, myocardial fibrosis or cardiac decompensation.
Steroid acids and salts. The primary bile acids are derived from cholesterol in the liver and usually conjugated with glycine or taurine. The secondary bile acids are further modified by bacteria in the intestine. They play an important role in the digestion and absorption of fat. They have also been used pharmacologically, especially in the treatment of gallstones.
A strongly basic anion exchange resin whose main constituent is polystyrene trimethylbenzylammonium Cl(-) anion.
A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.
An emulsifying agent produced in the LIVER and secreted into the DUODENUM. Its composition includes BILE ACIDS AND SALTS; CHOLESTEROL; and ELECTROLYTES. It aids DIGESTION of fats in the duodenum.
Software used to locate data or information stored in machine-readable form locally or at a distance such as an INTERNET site.
The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells.
Cells that line the inner and outer surfaces of the body by forming cellular layers (EPITHELIUM) or masses. Epithelial cells lining the SKIN; the MOUTH; the NOSE; and the ANAL CANAL derive from ectoderm; those lining the RESPIRATORY SYSTEM and the DIGESTIVE SYSTEM derive from endoderm; others (CARDIOVASCULAR SYSTEM and LYMPHATIC SYSTEM) derive from mesoderm. Epithelial cells can be classified mainly by cell shape and function into squamous, glandular and transitional epithelial cells.
A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.
Compounds based on fumaric acid.
Organic compounds containing the -CO-NH2 radical. Amides are derived from acids by replacement of -OH by -NH2 or from ammonia by the replacement of H by an acyl group. (From Grant & Hackh's Chemical Dictionary, 5th ed)
Agents that inhibit SODIUM CHLORIDE SYMPORTERS. They act as DIURETICS. Excess use is associated with HYPOKALEMIA.
Therapy with two or more separate preparations given for a combined effect.
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.
Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture.
Human COLORECTAL CARCINOMA cell line.
Men and women working in the provision of health services, whether as individual practitioners or employees of health institutions and programs, whether or not professionally trained, and whether or not subject to public regulation. (From A Discursive Dictionary of Health Care, 1976)
An agency of the PUBLIC HEALTH SERVICE concerned with the overall planning, promoting, and administering of programs pertaining to maintaining standards of quality of foods, drugs, therapeutic devices, etc.
The study of the origin, nature, properties, and actions of drugs and their effects on living organisms.
Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.
The branch of pharmacology that deals directly with the effectiveness and safety of drugs in humans.
Attitudes of personnel toward their patients, other professionals, toward the medical care system, etc.

Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. (1/41)

BACKGROUND: Small, dense LDL particles are associated with coronary artery disease (CAD) and predict angiographic changes in response to lipid-lowering therapy. Intensive lipid-lowering therapy in the Familial Atherosclerosis Treatment Study (FATS) resulted in significant improvement in CAD. This study examines the relationship among LDL density, hepatic lipase (HL), and CAD progression, identifying a new biological mechanism for the favorable effects of lipid-altering therapy. METHODS AND RESULTS: Eighty-eight of the subjects in FATS with documented coronary disease, apolipoprotein B levels >/=125 mg/dL, and family history of CAD were selected for this study. They were randomly assigned to receive lovastatin (40 mg/d) and colestipol (30 g/d), niacin (4 g/d) and colestipol, or conventional therapy with placebo alone or with colestipol in those with elevated LDL cholesterol levels. Plasma hepatic lipase (HL), lipoprotein lipase, and LDL density were measured when subjects were and were not receiving lipid-lowering therapy. LDL buoyancy increased with lovastatin-colestipol therapy (7.7%; P<0.01) and niacin-colestipol therapy (10.3%; P<0.01), whereas HL decreased in both groups (-14% [P<0.01] and -17% [P<0.01] with lovastatin-colestipol and niacin-colestipol, respectively). Changes in LDL buoyancy and HL activity were associated with changes in disease severity (P<0.001). In a multivariate analysis, an increase in LDL buoyancy was most strongly associated with CAD regression, accounting for 37% of the variance of change in coronary stenosis (P<0.01), followed by reduction in apolipoprotein Bl (5% of variance; P<0.05). CONCLUSIONS: These studies support the hypothesis that therapy-associated changes in HL alter LDL density, which favorably influences CAD progression. This is a new and potentially clinically relevant mechanism linking lipid-altering therapy to CAD improvement.  (+info)

Role of bile acids and bile acid binding agents in patients with collagenous colitis. (2/41)

BACKGROUND: In a retrospective study bile acid malabsorption was observed in patients with collagenous colitis. AIMS: To study the occurrence of bile acid malabsorption and the effect of bile acid binders prospectively in patients with chronic diarrhoea and collagenous colitis. METHODS: Over 36 months all patients referred because of chronic diarrhoea completed a diagnostic programme, including gastroscopy with duodenal biopsy, colonoscopy with biopsies, and the (75)Se-homocholic acid taurine ((75)SeHCAT) test for bile acid malabsorption. Treatment with a bile acid binder (cholestyramine in 24, colestipol in three) was given, irrespective of the results of the (75)SeHCAT test. RESULTS: Collagenous colitis was found in 28 patients (six men, 22 women), 27 of whom had persistent symptoms and completed the programme. Four patients had had a previous cholecystectomy or a distal gastric resection. The (75)SeHCAT test was abnormal in 12/27 (44%) of the collagenous colitis patients with (75)SeHCAT values 0.5-9.7%, and normal in 15 patients (56%). Bile acid binding treatment was followed by a rapid, marked, or complete improvement in 21/27 (78%) of the collagenous colitis patients. Rapid improvement occurred in 11/12 (92%) of the patients with bile acid malabsorption compared with 10/15 (67%) of the patients with normal (75)SeHCAT tests. CONCLUSION: Bile acid malabsorption is common in patients with collagenous colitis and is probably an important pathophysiological factor. Because of a high response rate without serious side effects, bile acid binding treatment should be considered for collagenous colitis, particularly patients with bile acid malabsorption.  (+info)

Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment. (3/41)

BACKGROUND: The common -514 C-->T polymorphism in the promoter region of the hepatic lipase (HL) gene affects HL activity. The C allele is associated with higher HL activity, more dense and atherogenic LDL, and lower HDL(2) cholesterol. Intensive lipid-lowering therapy lowers HL activity, increases LDL and HDL buoyancy, and promotes coronary artery disease (CAD) regression. We tested the hypothesis that subjects with the CC genotype and a more atherogenic lipid profile experience the greatest CAD regression from these favorable effects. METHODS AND RESULTS: Forty-nine middle-aged men with dyslipidemia and established CAD who were undergoing intensive lipid-lowering therapy were studied. Change in coronary stenosis was assessed by quantitative angiography, HL polymorphism by polymerase chain reaction amplification, HL activity by (14)C-labeled substrate, and LDL buoyancy by density-gradient ultracentrifugation. The response to lipid-lowering therapy was significantly different among subjects with different HL promoter genotypes. Subjects with the C:C genotype had the greatest decrease in HL activity (P<0.005 versus TC and TT by ANOVA) and the greatest improvement in LDL density (P<0.005) and HDL(2)-C (P<0.05) with therapy. These subjects had the greatest angiographic improvement, with 96% of them experiencing CAD regression, compared with 60% of TC and none of the TT patients (P:<0.001). CONCLUSIONS: -In middle-aged men with established CAD and dyslipidemia, the HL gene -514 C-->T polymorphism significantly predicts changes in coronary stenosis with lipid-lowering treatment that appear to involve an HL-associated effect on LDL metabolism. This study identifies a gene polymorphism that strongly influences the lipid and clinical response to lipid-lowering drugs.  (+info)

Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia. (4/41)

Interindividual variability in low density lipoprotein (LDL) cholesterol (LDL-C) response during treatment with statins is well documented but poorly understood. To investigate potential metabolic and genetic determinants of statin responsiveness, 19 patients with refractory heterozygous familial hypercholesterolemia were sequentially treated with placebo, atorvastatin (10 mg/d), bile acid sequestrant, and the 2 combined, each for 4 weeks. Levels of LDL-C, mevalonic acid (MVA), 7-alpha-OH-4-cholesten-3-one, and leukocyte LDL receptor and hydroxymethylglutaryl coenzyme A reductase mRNA were determined after each treatment period. Atorvastatin (10 mg/d) reduced LDL-C by an overall mean of 32.5%. Above-average responders (LDL-C -39.5%) had higher basal MVA levels (34.4+/-6.1 micromol/L) than did below-average responders (LDL-C -23.6%, P<0.02; basal MVA 26.3+/-6.1 micromol/L, P<0.01). Fewer good responders compared with the poor responders had an apolipoprotein E4 allele (3 of 11 versus 6 of 8, respectively; P<0.05). There were no baseline differences between them in 7-alpha-OH-4-cholesten-3-one, hydroxymethylglutaryl coenzyme A reductase mRNA, or LDL receptor mRNA, but the latter increased in the good responders on combination therapy (P<0.05). Severe mutations were not more common in poor than in good responders. We conclude that poor responders to statins have a low basal rate of cholesterol synthesis that may be secondary to a genetically determined increase in cholesterol absorption, possibly mediated by apolipoprotein E4. If so, statin responsiveness could be enhanced by reducing dietary cholesterol intake or inhibiting absorption.  (+info)

Growth hormone induces low-density lipoprotein clearance but not bile acid synthesis in humans. (5/41)

OBJECTIVE: Growth hormone (GH) induces hepatic low-density lipoprotein (LDL) receptors and lowers plasma cholesterol. We characterized the influence of GH treatment on plasma LDL clearance in normal humans and investigated the relative role of LDL receptor (LDLR) activity and stimulation of bile acid synthesis in subjects with different LDLR expression. METHODS AND RESULTS: Plasma clearance of autologous 125I-LDL was measured before and during 3 weeks of treatment with GH (0.1 IU/kg per day) in 9 healthy young males. Plasma LDL cholesterol was reduced by 13% and the fractional catabolic rate of LDL increased by 27%. More marked changes were seen in a patient with hypopituitarism substituted with GH (0.07 IU/kg per day) for 3 months. In a second study, GH dose-dependently reduced LDL cholesterol and increased Lp(a) levels in 3 groups of males: younger and elderly healthy subjects and heterozygous familial hypercholesterolemia (FH). No effect on bile acid synthesis measured by the plasma marker 7alpha-hydroxy-4-cholesten-3-one was observed. In an LDLR-deficient FH homozygote, LDL cholesterol was not affected by GH. CONCLUSIONS: GH treatment reduces plasma LDL cholesterol by inducing LDL clearance. In humans, LDLR expression is a prerequisite for this effect, whereas it is not related to stimulation of bile acid synthesis.  (+info)

Hepatic mRNA levels for the LDL receptor and HMG-CoA reductase show coordinate regulation in vivo. (6/41)

A sensitive solution hybridization assay using autologous cRNA probes was developed with the aim to study the simultaneous regulation of hepatic mRNA levels, on a quantitative basis, for the LDL receptor (LDLr), HMG-CoA reductase, and cholesterol 7 alpha-hydroxylase (Cho-7-hx) in C57BL/6J mice. With the purpose to suppress and stimulate transcript levels respectively, animals received established high fat diets, cholesterol-enriched diets, and a diet supplemented with mevinolin and colestipol. One hundred nineteen animals were investigated in six separate experiments. In spite of an eightfold increase in hepatic cholesterol induced by a high fat diet, the LDLr and the HMG-CoA reductase mRNA levels were only reduced to 60-70% and 25-50% of control values, respectively. When the data from all animals were analyzed, a strong positive correlation was obtained between the mRNA levels for the LDLr and HMG-CoA reductase (r = 0.79, P less than 0.001). A significant relation remained when control animals only were analyzed (n = 42, r = 0.59, P less than 0.001). Cho-7-hx mRNA showed a regulatory pattern that differed from that of the LDLr and HMG-CoA reductase; feeding cholesterol at 1.7% and 5% but not at 0.4% elevated the mRNA levels for Cho-7-hx while the LDLr and HMG-CoA reductase mRNA levels were maximally suppressed already at 0.4% of dietary cholesterol. The results show that the mRNA levels for the LDLr and HMG-CoA reductase are regulated in parallel in the liver in vivo during various metabolic perturbations as well as at normal physiologic conditions.(ABSTRACT TRUNCATED AT 250 WORDS)  (+info)

Comparison of computer- and human-derived coronary angiographic end-point measures for controlled therapy trials. (7/41)

The Cholesterol Lowering Atherosclerosis Study, a randomized angiographic clinical trial, demonstrated the beneficial effect of niacin/colestipol plus diet therapy on coronary atherosclerosis. Outcome was determined by panel-based estimates (viewed in both still and cine modes) of percent stenosis severity and change in native artery and bypass graft lesions. Computer-based quantitative coronary angiography (QCA) was also used to measure lesion and bypass graft stenosis severity and change in individual frames closely matched in orientation, opacification, and cardiac phase. Both methods jointly evaluated 350 nonoccluded lesions. The correlation between QCA and panel estimates of lesion size was 0.70 (p less than 0.0001) and for change in lesion size was 0.28 (p = 0.002). Agreement between the two methods in classifying lesion changes (i.e., regression, unchanged, or progression) occurred for 60% (210 of 350) of the lesions kappa +/- SEM = 0.20 +/- 0.05, p less than 0.001). The panel identified 442 nonoccluded lesions for which QCA stenosis measurements could not be obtained. Lesions not measurable by QCA included those with stenosis greater than 85% that could not be reliably edge tracked, segments with diffuse or ecstatic disease that had no reliable reference diameter, and segments for which matched frames could not be located. Seventy-nine lesions, the majority between 21% and 40% stenosis, were identified and measured by QCA but were not identified by the panel. This comparison study demonstrates the need to consider available angiographic measurement methods in relation to the goals of their use.  (+info)

Liver X receptor alpha interferes with SREBP1c-mediated Abcd2 expression. Novel cross-talk in gene regulation. (8/41)

The peroxisomal ATP binding cassette (ABC) transporter adrenoleukodystrophy-related protein, encoded by ABCD2, displays functional redundancy with the X-linked adrenoleukodystrophy-associated protein, making ABCD2 up-regulation of therapeutic value. Cholesterol lowering activates human ABCD2 in cultured cells. To investigate in vivo regulation by sterols, we first characterized a sterol regulatory element (SRE) in the murine Abcd2 promoter that is directly bound by SRE-binding proteins (SREBPs). Intriguingly, this element overlaps with a direct repeat 4, which serves as binding site for liver X receptor (LXR)/retinoid X receptor heterodimers, suggesting novel cross-talk between SREBP and LXR/retinoid X receptor in gene regulation. Using fasting-refeeding and cholesterol loading, SREBP accessibility to the SRE/direct repeat 4 was tested. Results suggest that adipose Abcd2 is induced by SREBP1c, whereas hepatic Abcd2 expression is down-regulated by concurrent activation of LXRalpha and SREBP1c. In cell culture, SREBP1c-mediated Abcd2 induction is counteracted by ligand-activated LXRalpha. Finally, hepatic Abcd2 expression in LXRalpha,beta-deficient mice is inducible to levels vastly exceeding wild type. Together, we identify LXRalpha as negative modulator of Abcd2, acting through a novel regulatory mechanism involving overlapping SREBP and LXRalpha binding sites.  (+info)

Since colestipol hydrochloride is an anion exchange resin, it may have a strong affinity for anions other than the bile acids. In vitro studies have indicated that colestipol hydrochloride binds a number of drugs. Therefore, COLESTID Tablets may delay or reduce the absorption of concomitant oral medication. The interval between the administration of COLESTID Tablets and any other medication should be as long as possible. Patients should take other drugs at least one hour before or four hours after COLESTID Tablets to avoid impeding their absorption.. Repeated doses of colestipol hydrochloride given prior to a single dose of propranolol in human trials have been reported to decrease propranolol absorption. However, in a follow-up study in normal subjects, single-dose administration of colestipol hydrochloride and propranolol and twice-a-day administration for 5 days of both agents did not affect the extent of propranolol absorption, but had a small yet statistically significant effect on its rate ...
The treatment of high blood cholesterol is entering a new phase. As in the treatment of hypertension, several drugs with different modes of action are now available, with more under study, kindling debates about their relative benefits and costs. The rationale and evidence for appropriate treatment of patients is becoming clearer, with the National Cholesterol Education Program guidelines leading the way. We are learning to decide which patients to treat with drug therapy and why, and we should all by now be familiar with how to use the available drugs. This study looks at drug treatment from a societal perspective by analyzing the cost-effectiveness of lowering cholesterol in an attempt to help the physician include costs in decisions about treatment. To simplify this, the authors used an LDL-HDL index to estimate the reduction in coronary heart disease morbidity and mortality for each cholesterol-lowering agent, based on the findings from the Lipid Research Clinics Primary Prevention Trial, ...
Atpase, ATP, Potassium, Sodium, Water, Membrane, Plasma, Atpases, Plasma Membrane, Kinase, Light, Epithelial Cells, and Membrane Proteins
The most common adverse reactions are confined to the gastrointestinal tract. To achieve minimal GI disturbance with an optimal LDL-cholesterol lowering effect, a gradual increase of dosage starting with one dose/day is recommended. Constipation is the major single complaint and at times is severe. Most instances of constipation are mild, transient, and controlled with standard treatment. Increased fluid intake and inclusion of additional dietary fiber should be the first step; a stool softener may be added if needed. Some patients require decreased dosage or discontinuation of therapy. Hemorrhoids may be aggravated.. Other, less frequent gastrointestinal complaints consist of abdominal discomfort (abdominal pain and cramping), intestinal gas, (bloating and flatulence), indigestion and heartburn, diarrhea and loose stools, and nausea and vomiting. Bleeding hemorrhoids and blood in the stool have been infrequently reported. Peptic ulceration, cholecystitis, and cholelithiasis have been rarely ...
The most common adverse reactions are confined to the gastrointestinal tract. To achieve minimal GI disturbance with an optimal LDL-C lowering effect, a gradual increase of dosage starting with 2 grams, once or twice daily is recommended. Constipation is the major single complaint and at times is severe. Most instances of constipation are mild, transient, and controlled with standard treatment. Increased fluid intake and inclusion of additional dietary fiber should be the first step; a stool softener may be added if needed. Some patients require decreased dosage or discontinuation of therapy. Hemorrhoids may be aggravated.. Other, less frequent gastrointestinal complaints consist of abdominal discomfort (abdominal pain and cramping), intestinal gas (bloating and flatulence), indigestion and heartburn, diarrhea and loose stools, and nausea and vomiting. Bleeding hemorrhoids and blood in the stool have been infrequently reported. Peptic ulceration, cholecystitis, and cholelithiasis have been ...
Take this medicine by mouth with a full glass of water. Follow the directions on the prescription label. Tablets must be taken one at a time and swallowed whole. Do not cut, crush or chew. Take other medicines at least 1 hour before or 4 hours after this medicine. Take your doses at regular intervals. Do not take your medicine more often than directed ...
The Cholesterol Lowering Atherosclerosis Study, a randomized, angiographic clinical trial, has demonstrated the beneficial effect of niacin/colestipol therapy on coronary and femoral atherosclerosis. The primary outcome was a panel-determined consensus score evaluating global coronary changes determined angiographically at 2 years. This article presents an evaluation of interreader agreement in independently assessing the status of native coronary arteries and overall coronary condition. Parameters include 1) identification of the presence of lesions and lesion changes; 2) estimation of lesion severity (percent stenosis) and amount of change in lesion severity; and 3) global assessment of change in coronary status. Readers independently agreed on 1) presence of lesions (82%) and change in lesions (51%); 2) percent stenosis +/- 10% (76%) and change in stenosis +/- 10% (81%); and 3) global assessment of change in coronary status within one step (96%). Results of these analyses may be useful in ...
FH is usually treated with statins.[7] Statins act by inhibiting the enzyme hydroxymethylglutaryl CoA reductase (HMG-CoA-reductase) in the liver. In response, the liver produces more LDL receptors, which remove circulating LDL from the blood. Statins effectively lower cholesterol and LDL levels, although sometimes add-on therapy with other drugs is required, such as bile acid sequestrants (cholestyramine or colestipol), nicotinic acid preparations or fibrates.[2] Control of other risk factors for cardiovascular disease is required, as risk remains somewhat elevated even when cholesterol levels are controlled. Professional guidelines recommend that the decision to treat a person with FH with statins should not be based on the usual risk prediction tools (such as those derived from the Framingham Heart Study), as they are likely to underestimate the risk of cardiovascular disease; unlike the rest of the population, FH have had high levels of cholesterol since birth, probably increasing their ...
GHC patients receive prescriptions through the GHC pharmacy at no or nominal cost. The GHC pharmacy database was established in January 1977. Its data files contain information on drug, dosage, quantity dispensed, prescription date, and instructions. Use of statin medications (simvastatin, lovastatin, pravastatin, and atorvastatin) and other lipid-lowering agents (LLAs), including niacin,cholestyramine, colestipol, gemfibrozil, and clofibrate, was defined as at least three filled prescriptions for statins or LLAs of 15 tablets or more. Subjects who did not use statins consistently with average daily dose (cumulative dose/duration ...
subjects on anticoagulant therapy (such as warfarin), taking medications and/or natural health products known to affect lipid metabolism (cholestyramine, colestipol, niacin, clofibrate, gemfibrozil, probucol, HMG CoA reductase inhibitors, high dose dietary supplements or fish oil capsules (,4g/day), guggul, lecithin, evening primrose oil within the last six month period will be excluded. In addition, subjects will not be allowed to consume any of these medications during the ...
It made me feel 90% better, vermox costo in farmacia but there was always a mild tingle in my crotch! Asegúrese de mencionar cualquiera de los siguientes: Inhibidores ECA; antiácidos que contienen aluminio (Maalox, vermox costo in farmacia Mylanta, otros); anticoagulantes (diluyentes de la sangre) como warfarina (Coumadin; Jantoven); bloqueadores de los canales de calcio tales como diltiazem (Cardizem, Cartia, Tiazac, otros), nicardipina (Cardene), nifedipina (Adalat, Procardia XL), y nisoldipina (Sular), colestiramina (Prevalite), cimetidina, ciprofloxacina (Cipro), clorpromazina, colestipol (Colestid), diazepam (Diastat, Valium), digoxina (Lanoxin), fluvoxamina (Luvox), haloperidol (Haldol), inhibidores de la HMG-CoA reductasa (agentes reductores de colesterol) como atorvastatina (Altoprev, Mevacor, en Advicor) y pravastatina (Pravachol), isoniacida (en Rifamate, en Rifater); los medicamentos para la depresión como bupropion (Aplenzin, Forfivo XL, Wellbutrin, Zyban), fluoxetina (Prozac, ...
Colestipol: Find the most comprehensive real-world treatment information on Colestipol at PatientsLikeMe. 15 patients with fibromyalgia, multiple sclerosis, major depressive disorder, generalized anxiety disorder, diabetes type 2, post-traumatic stress disorder, systemic lupus erythematosus, bipolar disorder, Parkinsons disease, panic disorder, rheumatoid arthritis, high blood pressure (hypertension), myalgic encephalomyelitis/chronic fatigue syndrome, persistent depressive disorder (dysthymia), amyotrophic lateral sclerosis, epilepsy, migraine, hypothyroidism, osteoarthritis, traumatic brain injury, bipolar II disorder, attention deficit/hyperactivity disorder, asthma, social anxiety disorder, high cholesterol (hypercholesterolemia), irritable bowel syndrome, idiopathic pulmonary fibrosis, gastroesophageal reflux disease, bipolar I disorder or psoriasis currently take Colestipol.
This medicine is mixed into a liquid and taken by mouth. DO NOT take this medicine in the dry form. Follow the directions on the prescription label. Add the granules to 3 or more ounces of water, milk, fruit juice, pulpy fruit juice, fluid soup, or other liquid. Mix well and drink all the liquid (it will not dissolve). Rinse the glass with some additional liquid and swallow to make sure you take the full dose. If you use a carbonated drink, use a larger glass as the mixture will foam. Take other medicines at least 1 hour before or 4 hours after this medicine. Take your medicine at regular intervals. Do not take it more often than directed.. Talk to your pediatrician regarding the use of this medicine in children. Special care may be needed.. Overdosage: If you think you have taken too much of this medicine contact a poison control center or emergency room at once.. NOTE: This medicine is only for you. Do not share this medicine with others.. ...
Do not use Generic Ziac if you are allergic to Generic Ziac components, to sulfa drugs or to any beta-blocker medication, such as atenolol (Tenormin), bisoprolol (Zebeta), labetalol (Normodyne, Trandate), nadolol (Corgard), propranolol (Inderal, InnoPran), sotalol (Betapace), timolol (Blocadren), and others.. Do not use Generic Ziac if youre pregnant or you plan to have a baby. Do not take it in case you are a nursing mother.. Do not use Generic Ziac if you are unable to urinate.. Do not use Generic Ziac if you have severe or uncontrolled heart failure, a heart condition called sick sinus syndrome or AV block or slow heartbeats.. Be careful with Generic Ziac if you have congestive heart failure, circulation problems, kidney or liver disease, cirrhosis, glaucoma, asthma, bronchospastic lung disease, a thyroid disorder, lupus, gout, diabetes, or a penicillin allergy.. Be careful with Generic Ziac if you take insulin or oral diabetes medication; colestipol (Colestid) or cholestyramine ...
PHENOBARBITAL with Lower blood vitamin E levels ., LAMOTRIGINE with Lower blood vitamin E levels ., GABAPENTIN with Lower blood vitamin E levels ., CLONAZEPAM with Lower blood vitamin E levels ., CISPLATIN with Dietary Substance is Drug Enhancer, COLESTIPOL with Decrease in Nutrient Level, DOXORUBICIN with Dietary Substance is Drug Enhancer, ORLISTAT with Decrease in Nutrient Level, VALPROIC ACID(SODIUM VALPROATE) with Decrease in Nutrient Level, NEOMYCIN with Decrease in Nutrient Level, CHOLESTYRAMINE with Decrease in Nutrient Level, WARFARIN with Increase in Nutrient Level, EXEMESTANE with Decrease in Nutrient Level, BEXAROTENE with Decrease in Nutrient Level, ...
Stacking Dosages of Clen. Clen is best recommended to take in the morning before you begin your exercise. Be it any kind of exercise or heavy work, Clen should always be taken 1 hour or 30 minutes before the task. It stays in the body for 24 hours. It has to be combined with a good fitness program to get maximum results. It becomes necessary to avoid supplements which include calcium or iron as it reacts with the thyroid hormones. One should also not take milk or dairy products when he is on thyroid medications. Some other medicines can also have aneffect on the T3 levels. Aspirin, danazol, and propranolol are known to increase T3 levels. Whereas lithium, methadone, furosemide, and colestipol decreases the T3 levels. It depends on how a person is taking the medications. One can personally monitor the dosage by noticing the behavior in the shaking of their hands.. Clenbuterol and T3. As stacking these two powerful drugs can deliver better results, it can also lead to some side-effects. Adding ...
Caution should subcitrate tired when intrinsic anti-inflammatory teats are cornified vastly with methotrexate. It is philly fatigued if colestipol is found in Prednisone milk. Limite la cheap zithromax buy de cafe?na que enfeebled bebe, aromatase caf?, t? y refrescos. You will buy prednisone to worsenabolish the buildings and bedclothes of offspring insulin lispro protaminensulin lispro vials while you are pregnant. In two 12-month studies, junior buy zithromax loss was stoned by 6 hyrdros and genetically preffered topomax loss was haunted over 12 months. Endocrineendocrine buy zithromax requires of lecthin use have included multivit and hyperglycemia. Monitor buttons for possibilities in Amoxicillin pressure and rearrangement rate. Acute findings should quisqualate ibruprofen with an inhaled, short-acting beta2-agonist disconnected as buy amoxicillin without a perscription (the neomycin should triphosphate the cytoskeleton with circumoral prolactin and ethanolate the rearrangement in how it ...
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details ...
1. Seven subjects were studied before and after the rate of cholesterol synthesis was altered with drugs or dietary cholesterol.. 2. The rate at which plasma free cholesterol was formed from squalene during constant infusions of radioactive mevalonate increased with colestipol treatment, decreased with clofibrate treatment and decreased when cholesterol was added to the diet. The plasma squalene concentration showed corresponding changes, confirming that its measurement may qualitatively define changes in cholesterol synthesis.. 3. The mean plasma squalene concentration in seven hypertriglyceridaemic, slightly overweight subjects was significantly higher than in six hypercholesterolaemic subjects, which is consistent with other evidence for increased cholesterol synthesis in hypertriglyceridaemia. ...
Take this medication by mouth with food, usually 1-3 times daily or as directed by your doctor. If you take this medicine once daily, take it with your evening meal. Taking niacin on an empty stomach increases side effects (e.g., flushing, upset stomach). Niacin is available in different formulations (e.g., immediate and sustained release). Do not switch other strengths, brands, or forms of niacin with this product. Severe liver problems may occur. Dosage is based on your medical condition and response to therapy. Generally, your doctor will start you at a low dose and gradually increase your dose in order to minimize side effects. Your dose will need to be increased slowly, even if you are already taking niacin and are being switched from another niacin product (e.g., extended-release) to this product. Follow your doctors instructions carefully. If you also take certain other drugs to lower your cholesterol (bile acid-binding resins such as cholestyramine or colestipol), take niacin at least ...
To improve mood try: http://www.philips.co.uk/c/light-therapy/38702/cat/. Vitamin D supplementation has also been shown to improve mood in some people. In one study supplementation with between 15-100ug was found to improve mood with the larger amount being more effective. The RDA - recommended daily amount is 5ug, but a generally safe and more effective amount for daily supplementation would be at least 25ug. In fact a single large dose of vitamin D is normally pretty safe also. For instance 30 minutes in the summer sun can easily produce 250ug of vitamin D, 50 times greater than the RDA. This mega dose is also pretty useful as the vitamin D remains in the body for a long time. It is possible to find out if your vitamin D levels are low via a blood test. If done privately through a Nutritional Therapist this would cost from £40. For most people supplementation will be safe to do, but if somebody is taking the following drugs: (Cholestyramine (Questran), colestipol (Colestid)), orlistat ...
Tell your doctor or pharmacist of all prescription and nonprescription drugs you may use, especially of: water pills (e.g., furosemide, spironolactone, triamterene), other drugs used to treat high blood pressure, corticosteroids (e.g., prednisone), NSAIDs (e.g., ibuprofen, naproxen, ketoprofen), certain diabetes medications (e.g., insulin, glyburide, glipizide), barbiturates (e.g., phenobarbital), narcotics (e.g., codeine), muscle relaxants (e.g., tubocurarine), sympathomimetic drugs (e.g., norepinephrine), lithium, ACTH (adrenocorticotropic hormone), tetracycline, cholestyramine, colestipol, digoxin, potassium supplements ...
Dofetilide or ketanserin because the risk of irregular heartbeat may be increased adrenocorticotropic hormone acth , barbiturates eg, phenobarbital , corticosteroids eg, prednisone , diuretics eg, furosemide , narcotic pain medicines eg, morphine , or other medicines for high blood pressure because they may increase the risk of avalide s side effects cholestyramine, colestipol, or nonsteroidal anti-inflammatory drugs nsaids eg, ibuprofen because they may decrease avalide s effectiveness diazoxide, digoxin, lithium, nondepolarizing muscle relaxants eg, tubocurarine , potassium, or potassium-sparing diuretics eg, spironolactone because risk of their side effects and toxic effects may be increased by avalide diabetes medicine eg, glipizide, metformin , insulin, or pressor amines eg, norepinephrine because their effectiveness may be decreased by avalide ...
Can you take aleve with coumadin. Purchase aleve. Aleve costa rica. Gabapentin interaction with aleve. Aleve or ibuprofen for pinched nerve. Can you alternate taking aleve and ibuprofen. Aleve ingredients naproxen sodium. Avapro advil vs aleve. Indomethacin vs aleve vs ibuprofen. Can i take aleve and prednisone. What is better for back pain motrin or aleve. Advil motrin aleve warnings. How much aleve can i take in a day. Benadryl quick dissolve strips ingredients in aleve. Imitrex and aleve together. Can u take aleve and ibuprofen together. blood pressure drugs cyclosporine carbamazepine; cholestyramine or colestipol; ; lithium; ritonavir digoxin, digitalis; rifampin; cancer drug, such as methotrexate or cyclophosphamide; a diuretic or water pill ; insulin or oral diabetic drugs; muscle relaxers, sedatives, narcotic pain drugs, sleeping pills,; nsaids non-steroidal anti-inflammatory drugs ibuprofen advil, motrin , naproxen aleve , celecoxib, indomethacin, meloxicam, diclofenac and others; or ...
If you also take bismuth salts (eg, bismuth subsalicylate), calcium salts (eg, calcium carbonate), colestipol, iron salts (eg, iron sulfate), magnesium, urinary alkalinizers (eg, daily antacids), sucralfate, vitamins/minerals, quinapril, didanosine, or zinc salts (eg, zinc sulfate), do not take them within 2 to 3 hours before or after taking Minocycline. Check with your doctor if you have questions ...
If you also take bismuth salts (eg, bismuth subsalicylate), calcium salts (eg, calcium carbonate), colestipol, iron salts (eg, iron sulfate), magnesium, urinary alkalinizers (eg, daily antacids), sucralfate, vitamins/minerals, quinapril, didanosine, or zinc salts (eg, zinc sulfate), do not take them within 2 to 3 hours before or after taking Minocin . Check with your doctor if you have questions ...
In a final effort to get the yellow out of my water, I tried a third brand of sequestrant/chelating agent, Sequa-Sol It worked. The water is the best looking it has been to date. The previous two were Metal Free and Sea Klear Metal Klear. The MSDS on this new one says the active ingredient is Sodium Citrate. It is listed as a chelating agent where the previous two used Acrylamide-Acrylic Acid Copolymer, listed as a sequestrant. I cant find much that explains the difference, at least as
The bile acid sequestrants are a group of resins used to bind certain components of bile in the gastrointestinal tract. They disrupt the enterohepatic circulation of bile acids by combining with bile constituents and preventing their reabsorption from the gut. In general, they are classified as hypolipidemic agents, although they may be used for purposes other than lowering cholesterol. They are used in the treatment of chronic diarrhea due to bile acid malabsorption. Bile acid sequestrants are polymeric compounds that serve as ion-exchange resins. Bile acid sequestrants exchange anions such as chloride ions for bile acids. By doing so, they bind bile acids and sequester them from the enterohepatic circulation. The liver then produces more bile acids to replace those that have been lost. Because the body uses cholesterol to make bile acids, this reduces the amount of LDL cholesterol circulating in the blood. Bile acid sequestrants are large polymeric structures, and they are not significantly ...
Bile acids promote bile formation and facilitate dietary lipid absorption. Animal and human studies showing disturbed bile acid metabolism in diabetes mellitus suggest a link between bile acids and glucose control. Bile acids are activating ligands of the farnesoid X receptor (FXR), a nuclear receptor with an established role in bile acid and lipid metabolism. Evidence suggests a role for FXR also in maintenance of glucose homeostasis. Animal and human studies employing bile acid sequestrants (bile acid binding agents), which interrupt the enterohepatic circulation of bile acids and effectively reduce plasma cholesterol, support a link between bile acid and glucose metabolism. In lipid-lowering trials, bile acid sequestrants, such as colesevelam hydrochloride, colestyramine (cholestyramine) and colestilan (colestimide), have also been shown to lower plasma glucose and glycosylated haemoglobin levels, suggesting the utility of these agents as a potential therapy for type 2 diabetes. In this ...
Learn more about Bile Acid Sequestrant Drugs at Grand Strand Medical Center Many Nutrients - Supplementation Likely Helpful The bile acid sequestrant...
Bile Acid SequestrantsPatients with terminal ileal disease may not absorb bile acids normally, which can lead to secretory diarrhea in the colon. These patients may benefit from bile acid sequestrants... more
vytorin hexal billig kaufen. vytorin pflaster preis - vytorin online - pflaster vytorin preisvergleich: Apotheke Inc Medical Supplies in Sandusky, OH - Wellness.I get muscle cramps could this be a side effect of simvastatin 40 mg? Find answers now! No. 1 Questions & Answers Place. More questions about Health, Diet & Fitness.Erektion uveitis q10 vs lipitor can I switch from to simvastatin can you. And hiv meds medicamento para el colesterol kamagra jelly preisvergleich einnahme a de 40.Simvastatin Sandoz 40 mg filmomhulde tabletten is doeltreffend alleen of in combinatie met anionuitwisselaars zoals colestyramine en colestipol.Apotheke, Preisvergleich und Testberichte. Preisvergleich - Apotheke. Simvastatin Corax 40 mg - Filmtabletten - 100 ST Corax Darreichungsform: Filmtabletten.. 1 Package leaflet Simvastatin XXX 40 mg, film-coated tablets Simvastatin Read all of this leaflet carefully before you start taking this medicine because it contains ...
This drug is not recommended for use with: dofetilide. Ask your doctor or pharmacist for more details. Inform your doctor about all the medicines you may use (both prescription and nonprescription), especially if you take: lithium, digoxin, oral drugs used for diabetes, aspirin, NSAIDs (e.g., ibuprofen, naproxen), fluconazole. If you take colestipol or cholestyramine for high cholesterol, take the diuretic 1 hour before or 4 hours after because of decreased absorption into the bloodstream. Avoid any drugs that increase your heart rate or make you excited like decongestants because it may counter-act your blood pressure medicine. Decongestants are commonly found in over the counter cough-and-cold products. Ask your pharmacist if you are uncertain about decongestants in over-the-counter products. Do not start or stop any medicine without doctor or pharmacist approval. ...
Therapy Drug-drug interactions displayed by pressing [f3] while in the list of drugs will now display details of each interaction. The listings for drug toxicity and interactions have been extensively updated and expanded Drugs added Levofloxacin Pharmacological profile Ampicillin-sulbactam, Cefotetan, Doxycycline, Meningococcal vaccine, Ofloxacin, Pyrimethamine / sulfadoxine Susceptibility database Eubacterium lentum Testing criteria Levofloxaxin Interactions database Atorvastatin, Colestipol, Insulin, Molindone, Pirenzepine, Zalcitabine Microbiology Note: A variety of fermentation and other reactions for gram-positive bacilli and non-fermentative gram-negative bacilli may require three or more days. The GIDEON data base allows for delayed positivity in such cases. Therefore, do not indicate a negative response for such organisms until at least three days have passed (see individual notes [F2] in the identification module). New taxa added Achromobacter group B, Achromobacter group E, ...
Many studies have demonstrated that progression of atherosclerosis can be suppressed by reduction of serum cholesterol levels. In these studies, however, histopathological changes of the atherosclerotic lesions have not been sufficiently examined. Results of our study show that a reduction of serum cholesterol levels due to pravastatin treatment altered the lesional composition of atherosclerotic plaques in WHHL rabbits.. In the present study we showed that a long-term reduction of serum cholesterol levels led to the following histopathological changes in the atherosclerotic plaques: (1) a decrease in the area of macrophages plus extracellular lipid deposits, (2) an increase in collagen area, (3) a suppression of the decrease in smooth muscle cell area with lesion progress, and (4) an increase in the ratio of collagen area to the area of extracellular lipid deposits (Tables 3⇑ and 5⇑).. In recent human studies, several groups reported on acute clinical coronary events. Becker and coworkers ...
Haque, Sahena, Gordon, Caroline, Isenberg, David, Rahman, Anisur, Lanyon, Peter, Bell, Aubrey, Emery, Paul, McHugh, Neil, Teh, Lee Suan, Scott, David G. I., Akil, Mohamed, Naz, Sophia, Andrews, Jacqueline, Griffiths, Bridget, Harris, Helen, Youseff, Hazem, McLaren, John, Toescu, Veronica, Devakumar, Vinodh, Teir, Jamal and Bruce, Ian N. (2010) Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) study. Journal of Rheumatology, 37 (2). pp. 322-329. Full text not available from this repository. (Request a copy ...
In Section 4.5 (Interactions) - Replacement of statement regarding interaction with cholestyramine with statement regarding interaction with bile acid sequestrants such as cholestyramine. - In Section 4.6 (Fertility, pregnancy and lactation) - Re-wording and addition of statement regarding a pre-clinical study.. - In Section 4.8 (Undesirable effects) - Deletion of list of symptoms of hypercalcaemia. Deletion of frequency number definitions from tabulation.. - Minor clarifications and re-wordings in sections 2, 4.2, 4.4 and 6.6 ...
Vytorin alternatives often include statins or other cholesterol medicines. This eMedTV article lists various types of statins and other classes of cholesterol medications, such as bile acid sequestrants, fibrates, and niacin.
Drugs to reduce cholesterol and other lipids in blood. Classes of drugs used for this purpose include statins, bile acid sequestrants, nicotinic acid, and fibrates.
Some anti-seizure medicines and bile acid sequestrants can react negatively with L-methylfolate. This eMedTV resource outlines other negative L-methylfolate drug interactions and describes some of the complications these reactions can cause.
Purpose of review: Diagnostic scoring for familial hypercholesterolaemia (FH) can be used either to screen for possible FH or guide the selection of patients for genetic (DNA) testing. We review the published diagnostic criteria and discuss the options for future development. Recent findings: Scoring systems have been developed internationally based on lipid values and various combinations of clinical signs and cardiovascular history. The predictive value varies according to the test population, be it lipid clinic referrals, general population, or relatives of patients with FH. Also, there is increasing recognition of genetic heterogeneity in FH so that criteria are of differing predictive value depending on the genetic variant of FH. Summary: These clinical scoring systems are increasingly used to guide selection of patients for FH genetic testing but no single approach has yet emerged as the system of choice. Further refinement of these scoring tools using more sophisticated calculators are ...
Pharmacology and key clinical studies of Lojuxta (lomitapide), a selective inhibitor of microsomal transfer protein (MTP) for homozygous familial hypercholesterolaemia.
Are you in need of a quick refresher on FH? Then this review article in the BMJ is for you. It is, however, not without inaccuracies and you could do worse than look up NICE Clinical Guideline 71 for a more thorough reading of the subject.
Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact [email protected] ...
Sonic Genetics provides word-class genetic testing through specialised genetic laboratories across Australia, the UK, Europe and the USA.
Davidson DJ, Wilkinson MJ, Davidson MH. Combination therapy for dyslipidemia. In: Ballantyne CM, ed. Clinical Lipidology: A Companion to Braunwalds Heart Disease. 2nd ed. Philadelphia, PA: Elsevier Saunders; 2015:chap 27.. Genest J, Libby P. Lipoprotein disorders and cardiovascular disease. In: Zipes DP, Libby P, Bonow RO, Mann DL, Tomaselli GF, Braunwald E, eds. Braunwalds Heart Disease: A Textbook of Cardiovascular Medicine. 11th ed. Philadelphia, PA: Elsevier; 2019:chap 48.. Goldberg AC. Bile acid sequestrants. In: Ballantyne CM, ed. Clinical Lipidology: A Companion to Braunwalds Heart Disease. 2nd ed. Philadelphia, PA: Elsevier Saunders; 2015:chap 22.. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):e285-e350. PMID: 30423393 ...
TY - JOUR. T1 - Familial hypercholesterolaemia. AU - Nair, Devaki R.. AU - Sharifi, Mahtab. AU - Al-Rasadi, Khalid. PY - 2014. Y1 - 2014. N2 - Increased awareness and wider availability of guidance to treat familial hypercholesterolaemia will improve management of familial hypercholesterolaemia. New therapies, if they become available after appropriate outcome studies, will reduce LDL-C levels in both homozygous familial hypercholesterolaemia and severe heterozygous familial hypercholesterolaemia, thus reducing the risk for premature CHD.. AB - Increased awareness and wider availability of guidance to treat familial hypercholesterolaemia will improve management of familial hypercholesterolaemia. New therapies, if they become available after appropriate outcome studies, will reduce LDL-C levels in both homozygous familial hypercholesterolaemia and severe heterozygous familial hypercholesterolaemia, thus reducing the risk for premature CHD.. KW - Familial hypercholesterolaemia. KW - Guidelines for ...
Bile acid sequestrants and nicotinic acid have cholesterollowering properties. They may occasionally be useful alone or in combination with statin therapy. However, their side-effects limit wider application.. 8.8 Treatment directed at other components of the lipid profile. Whereas low levels of HDL-C and high levels of TG are undoubtedly associated with a higher cardiovascular disease risk, no currently available treatment directed at reversing these changes has been shown to significantly benefit cardiovascular outcome.. A high triglyceride level, particularly if ,10 mmol/l, can result in acute pancreatitis and should be treated without delay.. 9. Special circumstances. 9.1 Metabolic syndrome. The European Guidelines recognise the importance of identifying patients with the metabolic syndrome, who are at increased risk of cardiovascular disease. The presence of the syndrome approximately doubles the risk of cardiovascular disease. Lifestyle changes, particularly reducing body weight and ...
Evidence-based recommendations on identifying and managing familial hypercholesterolaemia (inherited high cholesterol) for adults and children
The first aim was to critically evaluate the extent to which familial hypercholesterolaemia (FH) is underdiagnosed and undertreated. The second aim was to provide guidance for screening and treatment of FH, in order to prevent coronary heart disease (CHD ...
UCL Discovery is UCLs open access repository, showcasing and providing access to UCL research outputs from all UCL disciplines.
Cholestyramine, colestipol and colesevelam have all been used. Doses may not need to be as high as those previously used for ... Heel RC, Brogden RN, Pakes GE, Speight TM, Avery GS (March 1980). "Colestipol: a review of its pharmacological properties and ... Colestipol (Colestid, Colestipid) Colesevelam (Cholestagel in Europe, Welchol in the USA, Lodalis in Canada) FDA Heart Health ...
Colestipol is a weakly basic ion-exchange resin and is used to treat hypercholesterolemia. Cholestyramine is a strongly basic ... Colestipol and cholestyramine are known as bile acid sequestrants. Ion-exchange resins are also used as excipients in ... Three ion-exchange resins, sodium polystyrene sulfonate, colestipol, and cholestyramine, are used as active ingredients. Sodium ...
Cholestyramine and colestipol, both in powder form, have been used for many years. Unfortunately many patients find them ...
Colestipol in powder form in packages containing no more than 5 grams of the drug. Conjugated estrogen tablets when dispensed ...
If dietary treatment alone is insufficient, bile acid-binding resins (e.g., cholestyramine, colestipol) could be considered. In ...
... colestipol, and polystyrene sulfonate. Grapefruit juice may delay the absorption of levothyroxine, but based on a study of 10 ...
... colestipol or colesevelam, which may be better tolerated. Ultrasound of the abdominal cavity. General and biochemical blood. ...
C10AC02 Colestipol. C10AC03 Colextran. C10AC04 Colesevelam. C10AD Nicotinic acid and derivativesEdit. C10AD01 Niceritrol. ...
... colestipol, etc.): If taken together, bile acid resins may bind to fenofibrate, resulting in a decrease in fenofibrate ...
kolesteroolialandajad, näiteks colestipol,cholestyramine, colsevelam;. *epilepsiaravimid (ehk krampidevastased ravimid), ...
... cholestyramine or colestipol), nicotinic acid preparations or fibrates. Control of other risk factors for cardiovascular ...
... colestipol MeSH D25.720.259 --- cyanoacrylates MeSH D25.720.259.341 --- enbucrilate MeSH D25.720.259.341.110 --- bucrylate MeSH ...
... colestipol MeSH D02.092.782.258 --- diamines MeSH D02.092.782.258.174 --- cadaverine MeSH D02.092.782.258.368 --- ...
... colestipol (INN) colestolone (INN) colestyramine (INN) colextran (INN) colfenamate (INN) colforsin (INN) colfosceril palmitate ...
C10AB08 Ciprofibrate C10AB09 Etofibrate C10AB10 Clofibride C10AB11 Choline fenofibrate C10AC01 Colestyramine C10AC02 Colestipol ...
ISBN 3-8047-1763-2. Clinical Pharmacology: Colestipol structure Beth Israel Deaconess Medical Center & Care Group: Colestipol ... Colestipol is contraindicated in hypertriglyceridemia (high level of triglycerides in the blood).[citation needed] Colestipol ... Like cholestyramine, colestipol works in the gut by trapping bile acids and preventing them from being reabsorbed. This leads ... Colestipol (trade names Colestid, Cholestabyl) is a bile acid sequestrant used to lower blood cholesterol, specifically low- ...
On December 2, 2006 Pfizer cut off torcetrapib's phase III trial because of "an imbalance of mortality and cardiovascular events" associated with its use.[16] This was a sudden and unexpected event and as late as November 30, 2006 Jeff Kindler, Pfizer's chief executive, was quoted, "This will be one of the most important compounds of our generation."[16] In the terminated trial, a 60% increase in deaths was observed among patients taking torcetrapib and atorvastatin versus taking atorvastatin alone.[17] Pfizer recommended that all patients stop taking the drug immediately.[18] Six studies were terminated early.[6] One of the completed studies found it raised systolic blood pressure and concluded "Torcetrapib showed no clinical benefit in this or other studies, and will not be developed further."[19] The drug cost $800m+ to bring into Phase III development.[20] ...
Interactions with clofibrate, fenofibrate, gemfibrozil, which are fibrates used in accessory therapy in many forms of hypercholesterolemia, usually in combination with statins, increase the risk of myopathy and rhabdomyolysis.[38][42][43] Co-administration of atorvastatin with one of CYP3A4 inhibitors such as itraconazole,[44] telithromycin, and voriconazole, may increase serum concentrations of atorvastatin, which may lead to adverse reactions. This is less likely to happen with other CYP3A4 inhibitors such as diltiazem, erythromycin, fluconazole, ketoconazole, clarithromycin, cyclosporine, protease inhibitors, or verapamil,[45] and only rarely with other CYP3A4 inhibitors, such as amiodarone and aprepitant.[32] Often, bosentan, fosphenytoin, and phenytoin, which are CYP3A4 inducers, can decrease the plasma concentrations of atorvastatin. Only rarely, though, barbiturates, carbamazepine, efavirenz, nevirapine, oxcarbazepine, rifampin, and rifamycin,[46] which are also CYP3A4 inducers, can ...
Biosynthesis of mevastatin is primarily accomplished via a type 1 PKS pathway it proceeds in the PKS pathway as seen in figure 1 until it reaches a hexaketide state where it undergoes a Diels-Alder cyclization. After cyclization it continues via the PKS pathway to a nonaketide after which it is released and undergoes oxidation and dehydration. It is presumed that the oxidations are preformed by a polypeptide that is similar to cytochrome p450 monooxygenase, which is encoded by mlcC within the mevastatin gene. Lastly the biosynthesis is completed by the PKS facilitating the addition of a diketide sidechain and a methylation by SAM.[7] Figure 1 shows mevastatin in its acid form but it can also be in the more commonly seen lactone form. This pathway was first observed in Penicillium cilrinum and was later discovered that another type of fungus, Penicillium brevicompaetum also produced mevastatin via a PKS pathway. ...
The role of cholesterol in the development of cardiovascular disease was elucidated in the second half of the 20th century.[138] This lipid hypothesis prompted attempts to reduce cardiovascular disease burden by lowering cholesterol. Treatment consisted mainly of dietary measures, such as a low-fat diet, and poorly tolerated medicines, such as clofibrate, cholestyramine, and nicotinic acid. Cholesterol researcher Daniel Steinberg writes that while the Coronary Primary Prevention Trial of 1984 demonstrated cholesterol lowering could significantly reduce the risk of heart attacks and angina, physicians, including cardiologists, remained largely unconvinced.[139] Scientists in academic settings and the pharmaceutical industry began trying to develop a drug to reduce cholesterol more effectively. There were several potential targets, with 30 steps in the synthesis of cholesterol from acetyl-coenzyme A.[140] In 1971, Akira Endo, a Japanese biochemist working for the pharmaceutical company Sankyo, ...
... (trade names Advicor, Mevacor) is a drug combination used for the treatment of dyslipidemia. It is a combination of the vitamin niacin and the statin drug lovastatin. The combination preparation is marketed by Abbott Laboratories. It was approved by the FDA on December 17, 2001. ...
Colestipol (en) , klofibrato, pentoxifylline (en) , Alirocumab (en) , rosuvastatin (en) , clopidogrel (en) eta Evolocumab (en) ...
To determine the relative cost-effectiveness of lowering high blood cholesterol with cholestyramine, colestipol, gemfibrozil, ... Niacin and lovastatin were more efficient than gemfibrozil, probucol, colestipol, or cholestyramine for lowering cardiovascular ... Patients received monotherapy with cholestyramine, colestipol, niacin, gemfibrozil, lovastatin, or probucol compared with ... colestipol, or cholestyramine for lowering cardiovascular risk among patients with type II hyperlipoproteinemia and total ...
Alteration of aluminium inhibition of synaptosomal (Na(+)/K(+))ATPase by colestipol administration. Abstract ...
Peptic ulceration, cholecystitis, and cholelithiasis have been rarely reported in patients receiving colestipol hydrochloride ... Urticaria and dermatitis have been rarely noted in patients receiving colestipol hydrochloride granules. ... and alkaline phosphatase were observed on one or more occasions in various patients treated with colestipol hydrochloride. ...
As colestipol also binds bile acids, colestipol may reduce mycophenolic acid exposure and potentially reduce efficacy of ... Since colestipol hydrochloride is an anion exchange resin, it may have a strong affinity for anions other than the bile acids. ... When colestipol hydrochloride was administered in the diet to rats for 18 months, there was no evidence of any drug related ... Since colestipol hydrochloride is a chloride form of an anion exchange resin, there is a possibility that prolonged use may ...
Peptic ulceration, cholecystitis, and cholelithiasis have been rarely reported in patients receiving colestipol hydrochloride ... Urticaria and dermatitis have been rarely noted in patients receiving colestipol hydrochloride granules. ... and alkaline phosphatase were observed on one or more occasions in various patients treated with colestipol hydrochloride. ...
... has demonstrated the beneficial effect of niacin/colestipol therapy on coronary and femoral atherosclerosis. The primary ...
... colestipol (Colestid), diazepam (Diastat, Valium), digoxina (Lanoxin), fluvoxamina (Luvox), haloperidol (Haldol), inhibidores ...
... colestipol, gemfibrozil, and clofibrate, was defined as at least three filled prescriptions for statins or LLAs of 15 tablets ...
ISBN 3-8047-1763-2. Clinical Pharmacology: Colestipol structure Beth Israel Deaconess Medical Center & Care Group: Colestipol ... Colestipol is contraindicated in hypertriglyceridemia (high level of triglycerides in the blood).[citation needed] Colestipol ... Like cholestyramine, colestipol works in the gut by trapping bile acids and preventing them from being reabsorbed. This leads ... Colestipol (trade names Colestid, Cholestabyl) is a bile acid sequestrant used to lower blood cholesterol, specifically low- ...
Colestipol: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Before taking colestipol,. *tell your doctor and pharmacist if you are allergic to colestipol, any other medications, or any of ... Continue to take colestipol even if you feel well. Do not stop taking colestipol without talking to your doctor. ... Take colestipol exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. ...
Learn about the potential side effects of colestipol. Includes common and rare side effects information for consumers and ... Applies to colestipol: oral powder for suspension, oral tablet. Along with its needed effects, colestipol may cause some ... Applies to colestipol: oral granule for reconstitution, oral tablet. General. The most frequently reported side effects were ... Check with your doctor as soon as possible if any of the following side effects occur while taking colestipol:. More Common. * ...
... about interactions between Candesartan-Hydrochlorothiazide Oral and thiazide-related-diuretics-cholestyramine-colestipol. ... Effect of colestipol on gastrointestinal absorption of chlorothiazide in man. Clin Pharmacol Ther 1973 Sep-Oct; 14(5):886-90. ... 4.Hunninghake DB, King S, LaCroix K. The effect of cholestyramine and colestipol on the absorption of hydrochlorothiazide. Int ... Thiazide & Related Diuretics/Cholestyramine; Colestipol. This information is generalized and not intended as specific medical ...
Colestipol works by attaching to certain substances in the intestine. Since colestipol is not absorbed into the body, these ... Colestipol is used to lower high cholesterol levels in the blood. This may help prevent medical problems caused by cholesterol ... Colestipol may also be used for other conditions as determined by your doctor. ...
Find the most comprehensive real-world treatment information on Colestipol at PatientsLikeMe. 15 patients with fibromyalgia, ... bipolar I disorder or psoriasis currently take Colestipol. ... Currently taking Colestipol Duration. Patients. This item is ... Most popular types: Colestipol Suspension Colestid Flavored false Colestipol is a cholesterol-lowering drug. It is used as an ... Stopped taking Colestipol Duration. Patients. This item is relevant to you: 1 - 6 months 1 * 1 ...
Colestipol tablets. What is this medicine?. COLESTIPOL (koe LES ti pole) is used to lower cholesterol in patients who are at ... an unusual or allergic reaction to colestipol, other medicines, foods, dyes, or preservatives ...
Colestipol granules for oral suspension. What is this medicine?. COLESTIPOL (koe LES ti pole) is used to lower cholesterol in ... an unusual or allergic reaction to colestipol, other medicines, foods, dyes, or preservatives ...
Colestipol) drug information & product resources from MPR including dosage information, educational materials, & patient ... Colestipol HCl 5g/pkt or scoop; granules; orange flavored (contains aspartame, phenylalanine) or unflavored. ...
5 g of cellulose placebo; 5 g of colestipol; 2.5 g of colestipol plus 2.5 g of psyllium; or 5 g of psyllium three times daily ... Combination Therapy with Colestipol and Psyllium Mucilloid in Patients with Hyperlipidemia J. David Spence, MD; Murray W. Huff ... A combination of 2.5 g of psyllium and 2.5 g of colestipol was better tolerated than and as effective as either 5 g of ... Combination Therapy with Colestipol and Psyllium Mucilloid in Patients with Hyperlipidemia. Ann Intern Med. ;123:493-499. doi: ...
Probucol with Colestipol in the Treatment of Hypercholesterolemia Annals of Internal Medicine; 100 (4): 477-482 ... Colestipol and Probucol: Treatment of Primary and Familial Hypercholesterolemia and Amelioration of Atherosclerosis CHARLES J. ... Long-term colestipol therapy in conjunction with diet may reduce xanthoma size, arrest progression of coronary artery ... Complementarity of Colestipol, Niacin, and Lovastatin in Treatment of Severe Familial Hypercholesterolemia Annals of Internal ...
Description of the drug Colestipol hydrochloride. - patient information, description, dosage and directions. What is Colestipol ... Colestipol hydrochloride. Brand names: Colestid. Why is Colestipol hydrochloride prescribed?. Colestid, in conjunction with ... Why should Colestipol hydrochloride not be prescribed?. You should not be using Colestid if you are allergic to it or any of ... Recommended dosage for Colestipol hydrochloride. ADULTS. One packet or 1 level scoopful of Flavored Colestid granules or one ...
Colestipol); from expert pharmacists and people like you ... Colestid (Colestipol). 0 reports. These are side effects of. ... colestipol. at all.. *Percentages only tell you how common an issue is for people who actually make the effort to report side ... Colestid (Colestipol). questions for. Select an indication to see answers for that use case. Hyperlipidemia. ... Colestid (Colestipol) reported to the FDA by people taking it, and by doctors and pharmacists. ...
... What is this medicine?. COLESTIPOL (koe LES ti pole) is used to lower cholesterol in patients who are at ... an unusual or allergic reaction to colestipol, other medicines, foods, dyes, or preservatives ...
Colestipol Hydrochloride Oral suspension. What is this medicine?. COLESTIPOL (koe LES ti pole) is used to lower cholesterol in ... Colestipol Hydrochloride Oral tablet. What is this medicine?. COLESTIPOL (koe LES ti pole) is used to lower cholesterol in ... Colestipol Hydrochloride, Micronized Oral tablet. What is this medicine?. COLESTIPOL (koe LES ti pole) is used to lower ... an unusual or allergic reaction to colestipol, other medicines, foods, dyes, or preservatives ...
Colestipol (Colestid). Colestipol forms a soluble complex after binding to bile acid, increasing fecal loss of bile acid-bound ... These patients may benefit from bile acid sequestrants such as cholestyramine and colestipol. ...
colestipol was found in Daviss Drug Guide. Daviss Drug Guide for Nurses App + Web from F.A. Davis and Unbound Medicine covers ...
colestipol. Pain drugs. These drugs may decrease the effects of aliskiren/hydrochlorothiazide. This means that it may not work ...
colestipol. Depression drugs. Fluoxetine increases the amount of amlodipine/valsartan/hydrochlorothiazide in your body. This ...
... What is this medicine?. COLESTIPOL (koe LES ti pole) is used to lower cholesterol in ... an unusual or allergic reaction to colestipol, other medicines, foods, dyes, or preservatives ...
View full report on Colestipol Hydrochloride related fatigue Did the author experience fatigue while taking colestipol ... View full report on Colestipol Hydrochloride related alopecia Did the author experience alopecia while taking colestipol ... Colestipol Hydrochloride Side Effects. Filter Table by Serious Outcome. ×. Filter by Serious Outcome. ... View full report on Colestipol Hydrochloride related confusional state Did the author experience confusional state while taking ...
... ¿Qué es este medicamento?. El COLESTIPOL se utiliza para disminuir el colesterol de ... una reacción alérgica o inusual al colestipol, a otros medicamentos, alimentos, colorantes o conservantes ...
colestipol side effects diagn ib. the duration of the paroxysms the occurrence of intermis ... Colestipol drug: offset bv the observation of those who have been most. ... Colestipol Mechanism Of Action. admin 0 Comment colestipol mechanism of action colestipol dosage attended with stupefaction ... e y electricity colestipol drug colestipol uses When they are intimately mixed with the urine in such a way that ...
Colestipol forms a soluble complex after binding to bile acid, increasing fecal loss of bile acid-bound low-density lipoprotein ... These patients may benefit from bile acid sequestrants such as cholestyramine (2-4 g) and colestipol (5 g 2 or 3 times daily ... These patients may benefit from bile acid sequestrants such as cholestyramine and colestipol. ...
Cholestyramine Or Colestipol. Cholestyramine or Colestipol binds both levothyroxine (T4) and liothyronine (T3) in the intestine ... Therefore, four to five hours should elapse between administration of Cholestyramine or Colestipol and thyroid hormones. ...
Cholestyramine and Colestipol Resins. Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins ... certain cholesterol lowering medicines (resins that are used for cholesterol reduction, e.g.,cholestyramine and colestipol ...
Cholestyramine And Colestipol Resins. Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins ...
large doses of Colestipol hydrochloride are required for adequate therapeutic effect, and in renal failure, hepatic or ... ciclosporin levels should be carefully monitored if colestipol and ciclosporin are prescribed concurrently, as colestipol may ... Colestipol hydrochloride. CLINICAL USE Hyperlipidaemias, particularly type IIa. DOSE IN NORMAL RENAL FUNCTION 5 g once or twice ... Other drugs should be taken at least 1 hour before or 4-6 hours after colestipol to reduce possible interference with ...
  • In studies conducted in rats in which cholestyramine resin (a bile acid sequestering agent similar to colestipol hydrochloride) was used as a tool to investigate the role of various intestinal factors, such as fat, bile salts, and microbial flora, in the development of intestinal tumors induced by potent carcinogens, the incidence of such tumors was observed to be greater in cholestyramine resin treated rats than in control rats. (pfizermedicalinformationng.com)
  • Peptic ulceration, cholecystitis, and cholelithiasis have been rarely reported in patients receiving colestipol hydrochloride granules, and are not necessarily drug related. (pfizermedicalinformationng.com)
  • Transient and modest elevations of aspartate aminotransferase (AST, SGOT), alanine aminotransferase (ALT, SGPT) and alkaline phosphatase were observed on one or more occasions in various patients treated with colestipol hydrochloride. (pfizermedicalinformationng.com)
  • Urticaria and dermatitis have been rarely noted in patients receiving colestipol hydrochloride granules. (pfizermedicalinformationng.com)
  • Because it sequesters bile acids, colestipol hydrochloride may interfere with normal fat absorption and, thus, may reduce absorption of folic acid and fat soluble vitamins such as A, D, and K. (pfizermedicalinformationng.com)
  • Chronic use of colestipol hydrochloride may be associated with an increased bleeding tendency due to hypoprothrombinemia from vitamin K deficiency. (pfizermedicalinformationng.com)
  • Since colestipol hydrochloride is a chloride form of an anion exchange resin, there is a possibility that prolonged use may lead to the development of hyperchloremia acidosis. (pfizermedicalinformationng.com)
  • When colestipol hydrochloride was administered in the diet to rats for 18 months, there was no evidence of any drug related intestinal tumor formation. (pfizermedicalinformationng.com)
  • In the Ames assay, colestipol hydrochloride was not mutagenic. (pfizermedicalinformationng.com)
  • Since colestipol hydrochloride is essentially not absorbed systemically (less than 0.17% of the dose), it is not expected to cause fetal harm when administered during pregnancy in recommended dosages. (pfizermedicalinformationng.com)
  • Why is Colestipol hydrochloride prescribed? (drugster.info)
  • How should you take Colestipol hydrochloride? (drugster.info)
  • Why should Colestipol hydrochloride not be prescribed? (drugster.info)
  • Did the author experience fatigue while taking colestipol hydrochloride ? (druginformer.com)
  • The active ingredient in COLESTID Tablets is micronized colestipol hydrochloride, which is a lipid lowering agent for oral use. (pfizermedicalinformation.com.co)
  • Each COLESTID Tablet contains one gram of micronized colestipol hydrochloride. (pfizermedicalinformation.com.co)
  • Peptic ulceration, cholecystitis, and cholelithiasis have been rarely reported in patients receiving colestipol hydrochloride granules, and are not necessarily drug related. (pfizermedicalinformationng.com)
  • Transient and modest elevations of aspartate aminotransferase (AST, SGOT), alanine aminotransferase (ALT, SGPT) and alkaline phosphatase were observed on one or more occasions in various patients treated with colestipol hydrochloride. (pfizermedicalinformationng.com)
  • Urticaria and dermatitis have been rarely noted in patients receiving colestipol hydrochloride granules. (pfizermedicalinformationng.com)
  • Because it sequesters bile acids, colestipol hydrochloride may interfere with normal fat absorption and, thus, may reduce absorption of folic acid and fat soluble vitamins such as A, D, and K. (pfizermedicalinformationng.com)
  • Chronic use of colestipol hydrochloride may be associated with an increased bleeding tendency due to hypoprothrombinemia from vitamin K deficiency. (pfizermedicalinformationng.com)
  • Since colestipol hydrochloride is a chloride form of an anion exchange resin, there is a possibility that prolonged use may lead to the development of hyperchloremia acidosis. (pfizermedicalinformationng.com)
  • In studies conducted in rats in which cholestyramine resin (a bile acid sequestering agent similar to colestipol hydrochloride) was used as a tool to investigate the role of various intestinal factors, such as fat, bile salts, and microbial flora, in the development of intestinal tumors induced by potent carcinogens, the incidence of such tumors was observed to be greater in cholestyramine resin treated rats than in control rats. (pfizermedicalinformationng.com)
  • When colestipol hydrochloride was administered in the diet to rats for 18 months, there was no evidence of any drug related intestinal tumor formation. (pfizermedicalinformationng.com)
  • In the Ames assay, colestipol hydrochloride was not mutagenic. (pfizermedicalinformationng.com)
  • Since colestipol hydrochloride is essentially not absorbed systemically (less than 0.17% of the dose), it is not expected to cause fetal harm when administered during pregnancy in recommended dosages. (pfizermedicalinformationng.com)
  • To determine whether combined therapy with the lipid lowering agents colestipol hydrochloride plus niacin would produce significant change in coronary, carotid, and femoral artery atherosclerosis and coronary bypass graft lesions as determined by angiography. (clinicaltrials.gov)
  • One hundred eighty-eighty subjects were randomized to either 30 grams (g) of colestipol hydrochloride plus 3 to 12 g of niacin daily or to placebo. (clinicaltrials.gov)
  • Colestipol comes as tablets and granules to take by mouth. (medlineplus.gov)
  • Cholestyramine, colestipol and colesevelam have all been used. (wikipedia.org)
  • Cholesterol-lowering drugs such as cholestyramine (Questran) and colestipol (Colestid). (encyclopedia.com)
  • Colestipol (Colestid) is ineffective in the treatment of patients who completely lack LDL receptors due to a genetic defect ( homozygous familial hypercholesterolemia). (medicotips.com)
  • Colestipol plus nicotinic acid in treatment of heterozygous familial hypercholesterolemia. (pfizermedicalinformation.co.uk)
  • FDA Label, F4555, F4567, L6262] And even though such an agent may very well be useful in reducing elevated cholesterol levels and decreasing the risk for atherosclerotic vascular disease due to hypercholesterolemia, colestipol is still generally only employed as. (drugbank.ca)
  • Weight gain in four of five patients with hypercholesterolemia given colestipol for 37 +/- 6 months was associated with a decrease in HDL cholesterol levels and an increase in LDL cholesterol/HDL cholesterol ratios. (nih.gov)
  • These results suggest that weight reduction increases plasma HDL cholesterol levels only in those patients with hypercholesterolemia given colestipol but not in those given treatment by diet alone. (nih.gov)
  • A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction. (springer.com)
  • In the article entitled "Beneficial Effects of Combined Colestipol-Niacin Therapy on Coronary Atherosclerosis and Coronary Venous Bypass Grafts," Blankenhorn et al 1 presented exciting data concerning the possible stabilization of and improvement in coronary lesions in patients with a previous history of coronary bypass grafting who were treated with diet and cholesterol-reducing drugs. (jamanetwork.com)
  • Beneficial Effects of Combined Colestipol-Niacin Therapy on Coronary Atherosclerosis and Coronary Venous Bypass Grafts. (pfizermedicalinformation.co.uk)
  • Beneficial Effects of Colestipol-Niacin on Coronary Atherosclerosis: A 4-Year Follow-up. (pfizermedicalinformation.co.uk)
  • Such substances include: thiazide diuretics, furosemide gemfibrozil benzylpenicillin, tetracycline digoxin lipid-soluble vitamins (A, D, E, K) Colestipol is contraindicated in hypertriglyceridemia (high level of triglycerides in the blood). (wikipedia.org)
  • The following notable side effects may occur: gastrointestinal tract disturbances, especially (mild, occasionally severe) constipation sometimes increase in VLDL[citation needed] and triglyceride synthesis Colestipol can bind to a number of drugs and nutrients in the gut and inhibit or delay their absorption. (wikipedia.org)
  • Unless otherwise instructed, take all other medications at least 1 hour before or 4 hours after you take colestipol because it can interfere with their absorption. (medlineplus.gov)
  • Effect of colestipol on gastrointestinal absorption of chlorothiazide in man. (webmd.com)
  • 2.Hunninghake DB, King S. Effect of cholestyramine and colestipol on the absorption of methyldopa and hydrochlorothiazide. (webmd.com)
  • Colestipol (Colestid) bind with bile acids and impair their absorption and reduce enterohepatic circulation and re-utilization of bile acids. (medicotips.com)
  • Colestipol (Colestid) also decreases the absorption of dietary cholesterol. (medicotips.com)
  • In this way, Colestipol (Colestid) decrease the absorption of cholesterol and blood level of cholesterol is decreased. (medicotips.com)
  • Colestipol is in a class of medications called bile acid sequestrants. (medlineplus.gov)
  • These patients may benefit from bile acid sequestrants such as cholestyramine and colestipol. (medscape.com)
  • These patients may benefit from bile acid sequestrants such as cholestyramine (2-4 g) and colestipol (5 g 2 or 3 times daily before meals). (medscape.com)
  • Bile acid sequestrants like colestipol have been in use since the 1970s. (drugbank.ca)
  • Long-term colestipol therapy in conjunction with diet may reduce xanthoma size, arrest progression of coronary artery atherosclerosis, and may reduce mortality from coronary heart disease. (annals.org)
  • These are called colestyramine and colestipol. (nice.org.uk)
  • Colestyramine and colestipol have some side effects including constipation (when stools are not passed regularly), nausea (feeling sick), stomach rumbling, flatulence (wind), bloating and abdominal pain. (nice.org.uk)
  • colestipol mechanism of action colestipol dosage attended with stupefaction caused by blows on the head which cases and added the following and wishes to emphasize that traces or it may be absent altogether glomerular atrophy especially in colestipol side effects is more efficient or common than the abuse of intoxicating drinks. (guildwars2forum.com)
  • Familial type II hyperlipoproteinemia with coronary heart disease: Effect of diet-colestipol-nicotinic acid treatment. (pfizermedicalinformation.co.uk)
  • To test whether combining psyllium mucilloid with half the usual dose of colestipol reduces the adverse effects associated with colestipol and maintains or increases its efficacy in the treatment of hyperlipidemia. (annals.org)
  • COLESTIPOL (koe LES ti pole) is used to lower cholesterol in patients who are at risk of heart disease or stroke. (ahealthyme.com)
  • Colestipol (Colestid) is effective in reducing plasma cholesterol level (to about 10 - 20 % ) in patients with some normal LDL receptors. (medicotips.com)
  • Weight loss (-7 +/- 2 kg) in these five and two other patients given colestipol increased plasma HDL cholesterol (17% +/- 6%) and lowered total cholesterol (-8% +/- 1%), LDL cholesterol (-13% +/- 2%), and total triglyceride (-20% +/- 4%) concentrations. (nih.gov)
  • However, in six patients given treatment by diet alone (no colestipol), comparable weight loss (-6 +/- 1 kg) did not alter plasma HDL cholesterol or total triglyceride concentrations, but reduced total cholesterol (-9% +/- 3%) and LDL cholesterol (-11% +/- 3%) levels. (nih.gov)
  • The combination therapy and colestipol alone did not differ significantly with respect to changes in individual lipid values. (annals.org)
  • Is cholestyramine or colestipol better in effectiveness? (healthtap.com)
  • Colestipol is an insoluble, high molecular weight basic anion-exchange copolymer of diethylenetriamine and 1-chloro-2, 3-epoxypropane, with approximately 1 out of 5 amine nitrogens protonated (chloride form). (pfizermedicalinformation.com.co)
  • tell your doctor and pharmacist if you are allergic to colestipol, any other medications, or any of the ingredients in colestipol preparations. (medlineplus.gov)
  • citation needed] Colestipol is a copolymer of diethylenetriamine (DETA) -or tetraethylenepentamine according to some sources- and epichlorohydrin. (wikipedia.org)
  • Colestipol may cause side effects. (medlineplus.gov)
  • Some side effects of colestipol may occur that usually do not need medical attention. (drugs.com)
  • Colestipol is a safe, effective, cholesterol-lowering, bileacid sequestrant that lowers low-density-lipoprotein (LDL) and total plasma cholesterol levels without consistently affecting high-density-lipoprotein (HDL) cholesterol levels. (annals.org)